Skip to content

Conventional and Molecular Diagnostic Method for Patients With Suspected UTI

Conventional and Molecular Diagnostic Method for Patients With Suspected Urinary Tract Infections: Clinical, Economic, and Quality of Life Outcomes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02623179
Enrollment
50
Registered
2015-12-07
Start date
2016-01-15
Completion date
2016-12-31
Last updated
2017-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Tract Infections-UTI

Brief summary

In this protocol, the investigators are examining the use of a novel pathogen testing technology and method of identification of antibiotic susceptibility against the conventional C & S testing for patients with both complicated and uncomplicated UTIs. The investigators will examine the two modes in terms of objective patient related outcomes, i.e. 1) diagnostic accuracy and degree of detail of final analysis; 2) time to resolution of symptoms; 3) quality of life as defined by particularly symptomology and bothersomeness of the symptoms; and 4) overall cost.

Interventions

OTHERculture versus Molecular diagnostics

Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table

Sponsors

Southwest Regional PCR, LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* • Age greater than or equal to 18 and less than or equal to 89 years. * The PI suspects the patient has a complicated or uncomplicated UTI that requires urine testing to confirm diagnosis * Able to provide at least 8 ml urine total (urine for 2 pathology tests). * Is willing to complete one follow up surveys and send back to FH.

Exclusion criteria

* • Unable or unwilling to provide written informed consent. * Unable to read and write English (surveys are not available or validated in any other language than English). * Currently on any antibiotic for any clinical indication.

Design outcomes

Primary

MeasureTime frameDescription
To quantify differences in the relative abundance and presence of microbial lineages as determined by culture and sequencing technologies.1 yearcomparison of culture and sensitivity results to the molecular results

Secondary

MeasureTime frameDescription
Time (as measured in hours) to preliminary and final identification of organism(s) and antibiotic sensitivity(s) results1 yeartime from collection of sample to diagnostic result delivery
Time from participant reported start of UTI symptoms to resolution.1 yearcollect time of reported UTI from Subject
Participant Quality of Life as measured by a UTI specific severity and bothersome of symptoms survey taken at baseline (at clinic visit) and at set time points post urine testing1 yearcollect data from Subject as outlined in the Quality of Life Assessment
Overall cost1 yearcollect data on the overall cost of Subject treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026